FDA's clarification of the types of issues for which product sponsors may seek formal dispute resolution likely will serve to limit how often preliminary problems move up the chain of command within its drug and biologic product centers.
A revised draft guidance, "Formal Dispute Resolution: Appeals Above the Division Level," addresses the steps sponsors should take...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?